Journal of General Internal Medicine

, Volume 32, Issue 6, pp 660–666 | Cite as

Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention

  • Gail D’Onofrio
  • Marek C. Chawarski
  • Patrick G. O’Connor
  • Michael V. Pantalon
  • Susan H. Busch
  • Patricia H. Owens
  • Kathryn Hawk
  • Steven L. Bernstein
  • David A. Fiellin
Original Research

ABSTRACT

Background

Emergency department (ED)-initiated buprenorphine/naloxone with continuation in primary care was found to increase engagement in addiction treatment and reduce illicit opioid use at 30 days compared to referral only or a brief intervention with referral.

Objective

To evaluate the long-term outcomes at 2, 6 and 12 months following ED interventions.

Design

Evaluation of treatment engagement, drug use, and HIV risk among a cohort of patients from a randomized trial who completed at least one long-term follow-up assessment.

Participants

A total of 290/329 patients (88% of the randomized sample) were included. The followed cohort did not differ significantly from the randomized sample.

Interventions

ED-initiated buprenorphine with 10-week continuation in primary care, referral, or brief intervention were provided in the ED at study entry.

Main Measures

Self-reported engagement in formal addiction treatment, days of illicit opioid use, and HIV risk (2, 6, 12 months); urine toxicology (2, 6 months).

Key Results

A greater number of patients in the buprenorphine group were engaged in addiction treatment at 2 months [68/92 (74%), 95% CI 65–83] compared with referral [42/79 (53%), 95% CI 42–64] and brief intervention [39/83 (47%), 95% CI 37–58; p < 0.001]. The differences were not significant at 6 months [51/92 (55%), 95% CI 45–65; 46/70 (66%) 95% CI 54–76; 43/76 (57%) 95% CI 45–67; p = 0.37] or 12 months [42/86 (49%) 95% CI 39–59; 37/73 (51%) 95% CI 39–62; 49/78 (63%) 95% CI 52–73; p = 0.16]. At 2 months, the buprenorphine group reported fewer days of illicit opioid use [1.1 (95% CI 0.6–1.6)] versus referral [1.8 (95% CI 1.2–2.3)] and brief intervention [2.0 (95% CI 1.5–2.6), p = 0.04]. No significant differences in illicit opioid use were observed at 6 or 12 months. There were no significant differences in HIV risk or rates of opioid-negative urine results at any time.

Conclusions

ED-initiated buprenorphine was associated with increased engagement in addiction treatment and reduced illicit opioid use during the 2-month interval when buprenorphine was continued in primary care. Outcomes at 6 and 12 months were comparable across all groups.

KEY WORDS

opioid use disorder substance use disorder emergency medicine primary care 

References

  1. 1.
    Centers for Disease Control, Prevention. Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705–9.Google Scholar
  2. 2.
    Centers for Disease Control, Prevention. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.Google Scholar
  3. 3.
    Surgeon General Report: U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, Executive Summary. Washington, DC: HHS, November 2016.Google Scholar
  4. 4.
    Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.Google Scholar
  5. 5.
    Anonymous. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.Google Scholar
  6. 6.
    D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR: Text Revision: American Psychiatric Press Incorporated (DC); 2000.Google Scholar
  8. 8.
    Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet. 2002;359(9305):515–9.CrossRefPubMedGoogle Scholar
  9. 9.
    D’Onofrio G, Pantalon MV, Degutis LC, et al. Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med. 2008;51(6):742–50.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    D’Onofrio G, Pantalon MV, Degutis LC, et al. Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. Acad Emerg Med. 2005;12(3):249–56.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74–e11.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.CrossRefPubMedGoogle Scholar
  15. 15.
    McLellan TA, Zanis D, Incmikoski R. Treatment Service Review (TSR). Philadelphia: The Center for Studies in Addiction, Department of Psychiatry: Philadelphia VA Medical Center & The University of Pennsylvania; 1989.Google Scholar
  16. 16.
    McLellan AT, Alterman AI, Cacciola J, Metzger D. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992;180(2):101–10.CrossRefPubMedGoogle Scholar
  17. 17.
    Sobell L, Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992:41–72.CrossRefGoogle Scholar
  18. 18.
    Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk taking behaviour among intravenous drug users. Aids. 1991;5(2):181–186.CrossRefPubMedGoogle Scholar
  19. 19.
    IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.Google Scholar
  20. 20.
    Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–54.CrossRefPubMedGoogle Scholar
  21. 21.
    O’Connor P, Oliveto A, Shi J, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Suzuki J, Matthews ML, Brick D, et al. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and chronic pain patients using opioids non-medically. J Opioid Manag. 2014;10(3):159.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abus Treat. 2009;37(4):426–30.CrossRefGoogle Scholar
  25. 25.
    Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–31.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–20.CrossRefPubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2017

Authors and Affiliations

  • Gail D’Onofrio
    • 1
  • Marek C. Chawarski
    • 1
    • 2
  • Patrick G. O’Connor
    • 3
  • Michael V. Pantalon
    • 1
  • Susan H. Busch
    • 4
  • Patricia H. Owens
    • 1
  • Kathryn Hawk
    • 1
  • Steven L. Bernstein
    • 1
  • David A. Fiellin
    • 3
    • 4
  1. 1.Department of Emergency MedicineYale School of MedicineNew HavenUSA
  2. 2.Department of PsychiatryYale School of MedicineNew HavenUSA
  3. 3.Department of General MedicineYale School of MedicineNew HavenUSA
  4. 4.Yale School of Public HealthNew HavenUSA

Personalised recommendations